Sigrid Therapeutics’ Co-founder & CEO Sana Alajmovic named Sweden’s Female Founder of the Year 2021

Stockholm, Sweden, November 29, 2021. Amidst fierce competition from other stars of Sweden’s booming start-up scene, Sana Alajmovic, founder and CEO of healthtech company Sigrid Therapeutics, was voted the winner of the Female Founders competition 2021 as voted for by readers of leading industry publication Dagens Industri.

"It's a great honor, not least because many of the others nominated are my role models. It has been my goal to get more people outside the life science industry to pay attention to Sigrid and our work to prevent lifestyle diseases and contribute to a healthier world," Sana Alajmovic said in conjunction with the award ceremony at The Female Founders annual event.

This is the fifth year in a row that Di Digital's readers have named The Female Founder of the Year from a shortlist of 20 women in Sweden who have started a technology company.

"Everyone has had a positive impact on the digital business community in different ways. These include health care for women in developing countries, combating chronic diseases, femtech, homelessness, electrified trucks, recycling laundry water and several smart digital solutions," Di Digital writes.

"New tech companies today play an important role in the business world and the founders have become the new stars of our time."

Sigrid Therapeutics, which Sana Alajmovic founded together with Tore Bengtsson, professor of physiology at Stockholm University, aims to prevent two of the world's fastest growing lifestyle diseases - type 2 diabetes and obesity. Their lead product SiPore15® is a silica powder which can be easily taken mixed with water or food. SiPore15® does not enter the bloodstream, but instead acts locally in the gut by trapping the enzymes responsible for breaking down carbohydrates and fats. This enables blood sugar and other key levels to be managed.

The new share issue that recently raised SEK 72 million will be used to carry out one of the world's largest clinical studies on prediabetics and newly diagnosed type 2 diabetics in Europe in order to form the basis for the application for approval for SiPore15® as a medical device when completed. Sigrid also has plans to launch a new product, based on the Company’s proprietary platform technology SiPore®, in the nutritional supplement market in 2022.

For further information, please contact:

Sana Alajmovic, Co-founder, CEO & Board member, Sigrid Therapeutics

Telephone: +46 723 893 396


About Sigrid Therapeutics

Sigrid Therapeutics (Sigrid) is a clinical-stage healthtech company driven by the vision that no one should fall sick with chronic lifestyle diseases. The Company’s lead product SiPore15® is a patented silica-based powder clinically proven to lower long-term blood sugar and a range of metabolic parameters. Designed to act locally in the gut SiPore15® consists of precisely engineered micron-sized silica particles with tailored porosity capable of entrapping digestive enzymes inside the gut, lowering calorie uptake. Clinical studies with SiPore15® have shown a 1.4 mmol/mol reduction in long term blood sugar, HbA1c, in prediabetics after 3 months of consumption. This magnitude of reduction has been shown to reduce diabetes incidence in prediabetics by 31%.[1] To read more about Sigrid, visit

[1]Supported by studies conducted by Maruther 2013 (DPP),  ADA prediabetics 3000 pts, O´Brien et al 2015 and Aroda 2016 (DPPOS)